glp 1 price decrease GLP-1 reduction: President Trump announces deal to reduce costs You read that right 👀

Thats why GLP-1s are generally considered safe for non-diabetic use when prescribed appropriately

British Journal of Pharmacology (2022) 11

AOD-9604 targets obesity originally developed from a fragment of HGH, it is tailored to reduce adipose tissue mass and related metabolic conditions without affecting other bodily functions (5)

elife 6:e25496

As of early 2026, multiple Phase 3 trials have reported positive topline results, regulatory submissions have been filed, and the FDA is reviewing orforglipron for an obesity indication with a target action date of April 10, 2026

This layered approach allows us to move beyond single solutions and build a coordinated system that adapts with your body over time